Last reviewed · How we verify
Levodopa infusion
Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease.
Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease. Used for Advanced Parkinson's disease with motor fluctuations.
At a glance
| Generic name | Levodopa infusion |
|---|---|
| Also known as | Duodopa |
| Sponsor | University of Helsinki |
| Drug class | Dopamine precursor |
| Target | Dopamine (via AADC conversion) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Levodopa (L-DOPA) is a precursor to dopamine that crosses the blood-brain barrier, unlike dopamine itself. Once in the brain, it is converted to dopamine by the enzyme aromatic amino acid decarboxylase (AADC), restoring dopamine neurotransmission in the basal ganglia. The infusion formulation provides continuous delivery to maintain stable dopamine levels and reduce motor fluctuations in advanced Parkinson's disease.
Approved indications
- Advanced Parkinson's disease with motor fluctuations
Common side effects
- Dyskinesia
- Nausea
- Orthostatic hypotension
- Hallucinations
- Confusion
Key clinical trials
- Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
- AAV2-hAADC for Parkinson's Disease (PDCS-01) (PHASE1)
- Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease (PHASE3)
- Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease (PHASE3)
- Infusion of Apomorphine: Long-term Safety Study (PHASE3)
- A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (PHASE2)
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levodopa infusion CI brief — competitive landscape report
- Levodopa infusion updates RSS · CI watch RSS
- University of Helsinki portfolio CI